CDYL2 Epigenetically Regulates MIR124 to Control NF-κB/STAT3-Dependent Breast Cancer Cell Plasticity.

Area of Science:

• Epigenetics
• Cancer Biology
• Molecular Oncology

Background:

• Epigenetic deregulation of gene transcription drives cancer cell plasticity and progression.
• The role of the uncharacterized epigenetic factor chromodomain on Y-like 2 (CDYL2) in cancer is largely unknown.

Purpose of the Study:

• To investigate the role of CDYL2 in breast cancer.
• To elucidate the molecular mechanisms by which CDYL2 influences cancer cell phenotypes and prognosis.

Main Methods:

• Analysis of CDYL2 expression in breast cancer tissues.
• Functional assays assessing cell migration, invasion, stem-like phenotypes, and epithelial-to-mesenchymal transition.
• Investigation of signaling pathways including p65/NF-κB and STAT3.
• Chromatin immunoprecipitation assays to study the interaction of CDYL2 with epigenetic modifiers G9a/EHMT2 and EZH2 at MIR124 genes.

Main Results:

• CDYL2 is commonly overexpressed in breast cancer and correlates with poor prognosis.
• High CDYL2 levels promote breast cancer cell migration, invasion, stem-like properties, and epithelial-to-mesenchymal transition.
• CDYL2's effects are mediated through regulation of MIR124 gene transcription, leading to downstream activation of p65/NF-κB and STAT3 signaling.
• CDYL2 recruits epigenetic modifiers G9a and EZH2 to MIR124 gene loci, causing epigenetic repression.

Conclusions:

• CDYL2 is an oncogenic factor in breast cancer.
• CDYL2 contributes to poor prognosis by epigenetically silencing MIR124, thereby enhancing NF-κB and STAT3 signaling and promoting cancer cell plasticity and malignancy.